Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

421. Risk for schizophrenia and schizophrenia-like psychosis among patients with epilepsy: population based cohort study. Full Text available with Trip Pro

Risk for schizophrenia and schizophrenia-like psychosis among patients with epilepsy: population based cohort study. To investigate whether age at onset of epilepsy, type of epilepsy, family history of psychosis, or family history of epilepsy affect the risk of schizophrenia or schizophrenia-like psychosis among patients with epilepsy.Comparison of population based data.Danish longitudinal registers.The cohort comprised 2.27 million people.Epilepsy, psychosis, personal birth data.We found (...) an increased risk of schizophrenia (relative risk 2.48, 95% confidence interval 2.20 to 2.80) and schizophrenia-like psychosis (2.93, 2.69 to 3.20) in people with a history of epilepsy. The effect of epilepsy was the same in men and in women and increased with age. Family history of psychosis and a family history of epilepsy were significant risk factors for schizophrenia and schizophrenia-like psychosis, and the effect of epilepsy, both in cases and families, was greater among people with no family

2005 BMJ

422. Review: brain weight is reduced in people with schizophrenia Full Text available with Trip Pro

Review: brain weight is reduced in people with schizophrenia Review: brain weight is reduced in people with schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user (...) name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: brain weight is reduced in people with schizophrenia Article Text Aetiology Review: brain weight is reduced in people with schizophrenia Free Tim Crow , MB BS PhD DPM FRCP FRCPsych Statistics from Altmetric.com Harrison PJ, Freemantle N, Geddes JR. Meta

2005 Evidence-Based Mental Health

423. Aripiprazole is effective for relapse prevention in people with chronic stable schizophrenia Full Text available with Trip Pro

Aripiprazole is effective for relapse prevention in people with chronic stable schizophrenia Aripiprazole is effective for relapse prevention in people with chronic stable schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Aripiprazole is effective for relapse prevention in people with chronic stable schizophrenia Article Text Therapeutics Aripiprazole is effective for relapse prevention in people with chronic stable

2005 Evidence-Based Mental Health

424. Review: over 25% of people with schizophrenia, psychoses, or severe mental disorders fail to adhere to treatment programmes Full Text available with Trip Pro

Review: over 25% of people with schizophrenia, psychoses, or severe mental disorders fail to adhere to treatment programmes Review: over 25% of people with schizophrenia, psychoses, or severe mental disorders fail to adhere to treatment programmes | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: over 25% of people with schizophrenia, psychoses, or severe mental disorders fail to adhere to treatment programmes Article Text

2005 Evidence-Based Mental Health

425. Clinical and cost-effectiveness of electroconvulsive therapy for depressive illness, schizophrenia, catatonia and mania; systematic reviews and economic modelling studies Full Text available with Trip Pro

Clinical and cost-effectiveness of electroconvulsive therapy for depressive illness, schizophrenia, catatonia and mania; systematic reviews and economic modelling studies Clinical and cost-effectiveness of electroconvulsive therapy for depressive illness, schizophrenia, catatonia and mania; systematic reviews and economic modelling studies Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page

2005 NIHR HTA programme

426. Review: new generation antipsychotic drugs may reduce relapse rates more effectively than conventional antipsychotic drugs in people with schizophrenia Full Text available with Trip Pro

Review: new generation antipsychotic drugs may reduce relapse rates more effectively than conventional antipsychotic drugs in people with schizophrenia Review: new generation antipsychotic drugs may reduce relapse rates more effectively than conventional antipsychotic drugs in people with schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn (...) than conventional antipsychotic drugs in people with schizophrenia Article Text Therapeutics Review: new generation antipsychotic drugs may reduce relapse rates more effectively than conventional antipsychotic drugs in people with schizophrenia Free Andrew McIntosh , MPhil, MRCPsych , Stephen Lawrie , MD(Hons), MRCPsych Statistics from Altmetric.com Leucht S, Barnes TRE, Kissling W, et al . Relapse prevention in schizophrenia with new generation antipsychotics: a systematic review and exploratory

2005 Evidence-Based Mental Health

427. Aripiprazole is effective against the symptoms of schizophrenia and schizoaffective disorder Full Text available with Trip Pro

Aripiprazole is effective against the symptoms of schizophrenia and schizoaffective disorder Aripiprazole is effective against the symptoms of schizophrenia and schizoaffective disorder | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Aripiprazole is effective against the symptoms of schizophrenia and schizoaffective disorder Article Text Therapeutics Aripiprazole is effective against the symptoms of schizophrenia

2005 Evidence-Based Mental Health

428. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. Full Text available with Trip Pro

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The relative effectiveness of second-generation (atypical) antipsychotic drugs as compared with that of older agents has been incompletely addressed, though newer agents are currently used far more commonly. We compared a first-generation antipsychotic, perphenazine, with several newer drugs in a double-blind study.A total of 1493 patients with schizophrenia were recruited at 57 U.S. sites and randomly assigned

2005 NEJM Controlled trial quality: uncertain

429. Clinical and cost-effectiveness of electroconvulsive therapy for depressive illness, schizophrenia, catatonia and mania: systematic reviews and economic modelling studies

Clinical and cost-effectiveness of electroconvulsive therapy for depressive illness, schizophrenia, catatonia and mania: systematic reviews and economic modelling studies Clinical and cost-effectiveness of electroconvulsive therapy for depressive illness, schizophrenia, catatonia and mania: systematic reviews and economic modelling studies Clinical and cost-effectiveness of electroconvulsive therapy for depressive illness, schizophrenia, catatonia and mania: systematic reviews and economic (...) modelling studies Greenhalgh J, Knight C, Hind D, Beverley C, Walters S Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Greenhalgh J, Knight C, Hind D, Beverley C, Walters S. Clinical and cost-effectiveness of electroconvulsive therapy for depressive illness, schizophrenia, catatonia and mania: systematic reviews and economic modelling studies

2005 Health Technology Assessment (HTA) Database.

430. Case studies of adjunctive agents in clozapine-resistant schizophrenic patients

schizophrenic patients. Clinical Neuropharmacology 2005; 28(1): 50-53 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Adjuvants, Pharmaceutic /therapeutic use; Adolescent; Adult; Clozapine /therapeutic use; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Risperidone /therapeutic use; Schizophrenia /drug therapy AccessionNumber 12005006302 Date bibliographic record published 31/01/2007 Date abstract record published 31/01/2007 Record Status This is a critical abstract (...) Case studies of adjunctive agents in clozapine-resistant schizophrenic patients Case studies of adjunctive agents in clozapine-resistant schizophrenic patients Case studies of adjunctive agents in clozapine-resistant schizophrenic patients Kontaxakis V P, Ferentinos P P, Havaki-Kontaxaki B J, Paplos K G, Roukas D K, Christodoulou G N CRD summary This review examined case studies of the efficacy and safety of adjunctive agents in clozapine-resistant schizophrenic or schizoaffective patients

2005 DARE.

431. Evidence-based review of pharmacologic and nonpharmacologic treatments for older adults with schizophrenia

Evidence-based review of pharmacologic and nonpharmacologic treatments for older adults with schizophrenia Evidence-based review of pharmacologic and nonpharmacologic treatments for older adults with schizophrenia Evidence-based review of pharmacologic and nonpharmacologic treatments for older adults with schizophrenia Van Citters A D, Pratt S I, Bartels S J, Jeste D V CRD summary This review assessed the efficacy and safety of pharmacological and non-pharmacological interventions for older (...) adults with schizophrenia. The authors concluded that limited evidence suggests that these interventions can benefit older patients, but further research is required. The lack of a description of review methods and the use of multiple outcomes make it difficult to comment on the reliability of the evidence. Authors' objectives To evaluate the efficacy and safety of pharmacological and non-pharmacological interventions for older adults with schizophrenia. Searching Pharmacological studies were sought

2005 DARE.

432. Diffusion tensor imaging in schizophrenia

Diffusion tensor imaging in schizophrenia Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2005 DARE.

433. A comparison of olanzapine versus risperidone for the treatment of schizophrenia: a meta-analysis of randomised clinical trials

A comparison of olanzapine versus risperidone for the treatment of schizophrenia: a meta-analysis of randomised clinical trials A comparison of olanzapine versus risperidone for the treatment of schizophrenia: a meta-analysis of randomised clinical trials A comparison of olanzapine versus risperidone for the treatment of schizophrenia: a meta-analysis of randomised clinical trials Mudge M A, Davey P J, Coleman K A, Montgomery W, Croker V S, Mullen K, Castle D J CRD summary This review concluded (...) that olanzapine was superior to risperidone for a number of efficacy and safety variables, and these advantages may convey clinical relevance to certain aspects of schizophrenia. A lack of a systematic quality assessment and no details of the review methodology suggest that this conclusion should be treated with caution. Authors' objectives To compare the efficacy and safety of olanzapine with risperidone in the treatment of schizophrenia. Searching MEDLINE, EMBASE and the Cochrane Controlled Trials Register

2005 DARE.

434. Healthy living interventions and schizophrenia: a systematic review

Healthy living interventions and schizophrenia: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2005 DARE.

435. The effect of cognitive behavioral treatment on the positive symptoms of schizophrenia spectrum disorders: a meta-analysis

The effect of cognitive behavioral treatment on the positive symptoms of schizophrenia spectrum disorders: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2005 DARE.

436. Efficacy and effectiveness of an exercise program as community support for schizophrenic patients

Efficacy and effectiveness of an exercise program as community support for schizophrenic patients Efficacy and effectiveness of an exercise program as community support for schizophrenic patients Efficacy and effectiveness of an exercise program as community support for schizophrenic patients Torres-Carbajo A, Olivares J M, Merino H, Vazquez H, Diaz A, Cruz E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study compared two outpatient treatment strategies for patients suffering from schizophrenia. These were "standard care" and "exercise programme". "Standard care" comprised outpatient visits to a mental health clinic once a month, with an average meeting duration of 15 minutes during which psychotherapeutic

2005 NHS Economic Evaluation Database.

437. North Wales randomized controlled trial of cognitive behaviour therapy for acute schizophrenia spectrum disorders: two-year follow-up and economic evaluation

North Wales randomized controlled trial of cognitive behaviour therapy for acute schizophrenia spectrum disorders: two-year follow-up and economic evaluation Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2005 NHS Economic Evaluation Database.

438. Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs Full Text available with Trip Pro

Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated (...) (or atypical antipsychotics) for the treatment of schizophrenia. Each strategy comprised a first-line treatment, followed by alternative therapies if the patient did not respond to treatment. The three strategies were as follows. The risperidone strategy comprised initial treatment with long-acting risperidone, followed by a first alternative of olanzapine, a second alternative of clozapine, and a third alternative of depot haloperidol. The depot haloperidol strategy comprised initial treatment with depot

2005 NHS Economic Evaluation Database.

439. Modelling the treated course of schizophrenia: development of a discrete event simulation model

Modelling the treated course of schizophrenia: development of a discrete event simulation model Modelling the treated course of schizophrenia: development of a discrete event simulation model Modelling the treated course of schizophrenia: development of a discrete event simulation model Heeg B M, Buskens E, Knapp M, van Aalst G, Dries P J, de Haan L, van Hout B A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined unspecified methods to increase compliance (by 20%) with therapies for the treatment of schizophrenia. Initially, conventional antipsychotic medication was administered. This was switched to atypical antipsychotic drugs and, subsequently, to clozapine if the administered treatment was ineffective

2005 NHS Economic Evaluation Database.

440. Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis

, Lichtenberg P, Kaplan Z, et al. Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics. Am J Psychiatry 2001;158:266-9. Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002;346:16-22. Laux G, Heeg B, van Hout B, et al. Costs and effects of long-acting risperidone compared with oral atypical and conventional (...) depot formulations in Germany. Pharmacoeconomics 2005;23 Suppl 1:49-61. Heeg BM, van Aalst G, van den Arend JJ, et al. A discrete events model of long-term outcomes and cost of treatment with long acting risperidone in schizophrenia. Value in Health 2003;6:515-6. Llorca PM, Miadi-Fargier H, Lancon C, et al. Cost-effectiveness of schizophrenic patient care strategies: impact of an atypical antipsychotic in a long-acting infection formulation. L'Encephale 2005;31:235-46. Indexing Status Subject

2005 NHS Economic Evaluation Database.